NCT04840472View on ClinicalTrials.gov

Study Evaluating 111In-Panitumumab for Nodal Staging in Head and Neck Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

March 30, 2021

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Head and Neck Cancer
Interventions
DRUG

111I-n panitumumab

Imaging Agent

PROCEDURE

Single photon emission computed tomography/computed tomography (SPECT/CT) scans

Day 1 to 5 (Day of Surgery inclusive)

Trial Locations (1)

94305

RECRUITING

Stanford University, Stanford

All Listed Sponsors
collaborator

American Cancer Society, Inc.

OTHER

lead

Andrei Iagaru

OTHER

NCT04840472 - Study Evaluating 111In-Panitumumab for Nodal Staging in Head and Neck Cancer | Biotech Hunter | Biotech Hunter